• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Baudax Bio, Inc. - Common stock (NQ:BXRX)

N/A UNCHANGED
Last Price Updated: 3:50 PM EST, Nov 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Baudax Bio, Inc. - Common stock

Watchlist Alert: Nasdaq Stocks Under $1 Experience Volume Breakouts: KAVL, BXRX, RMED, SMX
July 06, 2023
Via AB Newswire
News headline image
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
May 12, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio to Present at the Sidoti Virtual Investor Conference
May 03, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Closing of $4 Million Public Offering
May 01, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Pricing of $4 Million Public Offering
April 26, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
April 25, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
April 24, 2023
Virtual Webinar to be held April 25, 2023 at 10:00 AM Eastern Time 
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
March 27, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
February 23, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
January 25, 2023
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. 
Via MarketBeat
News headline image
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
January 24, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
December 30, 2022
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Baudax Bio (NASDAQ: BXRX) Launches Phase 2 Clinical Trial Testing BX1000 for Neuromuscular Blockade in Patients Undergoing Surgery
December 09, 2022
Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use 
Via Spotlight Growth
News headline image
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
December 08, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Closing of $5 Million Public Offering
December 06, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces Pricing of $5 Million Public Offering
December 02, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Announces 1-for-40 Reverse Stock Split
November 30, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
News headline image
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
November 08, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap